These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7198201)

  • 1. Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents.
    Rafal RD; Grimm RJ
    Neurology; 1981 Dec; 31(12):1507-18. PubMed ID: 7198201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of progressive supranuclear paralysis. Effect of methysergide and bromocriptine on various psychoneurologic and motor functions].
    Giménez-Roldán S; de Andrés C; Salinero E
    Rev Clin Esp; 1979 Apr; 153(1):21-7. PubMed ID: 461893
    [No Abstract]   [Full Text] [Related]  

  • 3. Methysergide in progressive supranuclear palsy.
    Duncombe AS; Lees AJ
    Neurology; 1985 Jun; 35(6):936-7. PubMed ID: 4000498
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacological therapy in progressive supranuclear palsy.
    Kompoliti K; Goetz CG; Litvan I; Jellinger K; Verny M
    Arch Neurol; 1998 Aug; 55(8):1099-102. PubMed ID: 9708960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive supranuclear palsy (the Steele-Richardson-Olszewski syndrome) clinical and electrophysiological observations in eleven cases.
    Mastaglia FL; Grainger K; Kee F; Sadka M; Lefroy R
    Proc Aust Assoc Neurol; 1973; 10(0):35-44. PubMed ID: 4792160
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of progressive supranuclear palsy with methysergide. A clinical study.
    Di Trapani G; Stampatore P; La Cara A; Azzoni A; Vaccario ML
    Ital J Neurol Sci; 1991 Apr; 12(2):157-61. PubMed ID: 2071361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progressive supranuclear palsy. Diagnostic problems].
    Kristensen MO
    Ugeskr Laeger; 1985 Sep; 147(39):3074-5. PubMed ID: 4071761
    [No Abstract]   [Full Text] [Related]  

  • 8. The treatment of progressive supranuclear palsy with L-dopa.
    Donaldson IM
    Aust N Z J Med; 1973 Aug; 3(4):413-6. PubMed ID: 4519129
    [No Abstract]   [Full Text] [Related]  

  • 9. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.
    Jankovic J
    Neurology; 1983 Apr; 33(4):505-7. PubMed ID: 6339985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive supranuclear palsy (report of 4 cases with particular reference to blepharospasm and levodopa therapy).
    Singh S; Smith BH; Lal A
    Neurol India; 1974 Jun; 22(2):65-71. PubMed ID: 4437701
    [No Abstract]   [Full Text] [Related]  

  • 11. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).
    Maher ER; Lees AJ
    Neurology; 1986 Jul; 36(7):1005-8. PubMed ID: 3714047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-dopa for progressive supranuclear palsy.
    Jenkins R
    Lancet; 1969 Oct; 2(7623):742. PubMed ID: 4186183
    [No Abstract]   [Full Text] [Related]  

  • 13. Neurofibrillary tangles in progressive supranuclear palsy. Electron microscopic observations.
    Powell HC; London GW; Lampert PW
    J Neuropathol Exp Neurol; 1974 Jan; 33(1):98-106. PubMed ID: 4812327
    [No Abstract]   [Full Text] [Related]  

  • 14. [Progressive supranuclear paralysis. Critical review, with a note on verbal expression disorders and action of L-dopa].
    Giménez-Roldán S; Esteban A
    Arch Neurobiol (Madr); 1972; 35(1):41-60. PubMed ID: 5060240
    [No Abstract]   [Full Text] [Related]  

  • 15. [Progressive supranuclear paralysis. A case with "apraxia of the eye opening" and favorable response to treatment with L-dopa].
    Dehaene I; Bogaerts M
    Acta Neurol Belg; 1971; 71(2):141-5. PubMed ID: 5000585
    [No Abstract]   [Full Text] [Related]  

  • 16. Progressive supranuclear palsy: pneumoencephalography, electronystagmography and treatment with methysergide.
    Paulson GW; Lowery HW; Taylor GC
    Eur Neurol; 1981; 20(1):13-6. PubMed ID: 7202438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy.
    Goetz CG; Leurgans S; Lang AE; Litvan I
    Neurology; 2003 Mar; 60(6):917-22. PubMed ID: 12654953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical presentation of progressive supranuclear palsy.
    Davis PH; Bergeron C; McLachlan DR
    Ann Neurol; 1985 Apr; 17(4):337-43. PubMed ID: 4004154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Frontal syndrome of progressive supranuclear palsy].
    Cambier J; Masson M; Viader F; Limodin J; Strube A
    Rev Neurol (Paris); 1985; 141(8-9):528-36. PubMed ID: 4089415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy.
    Neophytides A; Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Bock J; Walker R
    J Neurol Neurosurg Psychiatry; 1982 Mar; 45(3):261-3. PubMed ID: 7086448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.